These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 27354719)

  • 1. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.
    Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Grønbæk K; Sundberg J; Pedersen LB; Ralfkiær E; Karjalainen-Lindsberg ML; Sundström C; Ehinger M; Geisler C; Jerkeman M
    Blood; 2016 Oct; 128(14):1814-1820. PubMed ID: 27354719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi.
    Visco C; Chiappella A; Nassi L; Patti C; Ferrero S; Barbero D; Evangelista A; Spina M; Molinari A; Rigacci L; Tani M; Rocco AD; Pinotti G; Fabbri A; Zambello R; Finotto S; Gotti M; Carella AM; Salvi F; Pileri SA; Ladetto M; Ciccone G; Gaidano G; Ruggeri M; Martelli M; Vitolo U
    Lancet Haematol; 2017 Jan; 4(1):e15-e23. PubMed ID: 27927586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL.
    Smith MR; Jegede OA; Martin P; Till BG; Parekh SS; Yang DT; Hsi ED; Witzig T; Dave S; Scott D; Hanson C; Kostakoglu Shields L; Abdel-Samad N; Casulo C; Bartlett NL; Caimi PF; Al Baghdadi T; Blum KA; Romer MD; Inwards DJ; Lerner RE; Wagner LI; Little RF; Friedberg JW; Leonard JP; Kahl BS
    Blood; 2024 Sep; 144(10):1083-1092. PubMed ID: 38820500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
    Wang M; Fayad L; Wagner-Bartak N; Zhang L; Hagemeister F; Neelapu SS; Samaniego F; McLaughlin P; Fanale M; Younes A; Cabanillas F; Fowler N; Newberry KJ; Sun L; Young KH; Champlin R; Kwak L; Feng L; Badillo M; Bejarano M; Hartig K; Chen W; Chen Y; Byrne C; Bell N; Zeldis J; Romaguera J
    Lancet Oncol; 2012 Jul; 13(7):716-23. PubMed ID: 22677155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tafasitamab Plus Lenalidomide Versus 3 Rituximab-Based Treatments for Non-Transplant Eligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Matching-Adjusted Indirect Comparison.
    Cordoba R; Prawitz T; Westley T; Sharma A; Ambarkhane S; Kapetanakis V; Sabatelli L
    Adv Ther; 2022 Jun; 39(6):2668-2687. PubMed ID: 35403948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study.
    Matsumoto K; Takayama N; Aisa Y; Ueno H; Hagihara M; Watanabe K; Nakaya A; Chen K; Shimizu T; Tsukada Y; Yamada Y; Nakazato T; Ishida A; Miyakawa Y; Yokoyama K; Nakajima H; Masuda Y; Yano T; Okamoto S;
    Int J Hematol; 2015 Jun; 101(6):554-62. PubMed ID: 25783753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
    Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
    Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.
    Ruan J; Martin P; Shah B; Schuster SJ; Smith SM; Furman RR; Christos P; Rodriguez A; Svoboda J; Lewis J; Katz O; Coleman M; Leonard JP
    N Engl J Med; 2015 Nov; 373(19):1835-44. PubMed ID: 26535512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.
    Jerkeman M; Eskelund CW; Hutchings M; Räty R; Wader KF; Laurell A; Toldbod H; Pedersen LB; Niemann CU; Dahl C; Kuitunen H; Geisler CH; Grønbæk K; Kolstad A
    Lancet Haematol; 2018 Mar; 5(3):e109-e116. PubMed ID: 29396091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
    Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
    Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
    Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
    Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings.
    Czuczman MS; Goy A; Lamonica D; Graf DA; Munteanu MC; van der Jagt RH
    Ann Hematol; 2015 Dec; 94(12):2025-32. PubMed ID: 26411584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.
    Ogura M; Ishizawa K; Maruyama D; Uike N; Ando K; Izutsu K; Terui Y; Imaizumi Y; Tsukasaki K; Suzuki K; Izumi T; Usuki K; Kinoshita T; Taniwaki M; Uoshima N; Suzumiya J; Kurosawa M; Nagai H; Uchida T; Fukuhara N; Choi I; Ohmachi K; Yamamoto G; Tobinai K;
    Int J Hematol; 2017 Apr; 105(4):470-477. PubMed ID: 27900638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
    Witzig TE; Nowakowski GS; Habermann TM; Goy A; Hernandez-Ilizaliturri FJ; Chiappella A; Vitolo U; Fowler N; Czuczman MS
    Ann Oncol; 2015 Aug; 26(8):1667-77. PubMed ID: 25712458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRD-driven treatment with venetoclax-R2 in mantle cell lymphoma: the Nordic Lymphoma Group MCL7 VALERIA trial.
    Jerkeman M; Kolstad A; Hutchings M; Pasanen A; Meriranta L; Niemann CU; Kragh Jørgensen RR; El-Galaly TC; Riise J; Leppä S; Christensen JH; Sonnevi K; Pedersen LB; Wader KF; Glimelius I
    Blood Adv; 2024 Jan; 8(2):407-415. PubMed ID: 38113470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    Chang JE; Havighurst T; Kim K; Eickhoff J; Traynor AM; Kirby-Slimp R; Volk LM; Werndli J; Go RS; Weiss M; Blank J; Kahl BS
    Br J Haematol; 2016 Apr; 173(2):283-91. PubMed ID: 26913697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
    Hitz F; Zucca E; Pabst T; Fischer N; Cairoli A; Samaras P; Caspar CB; Mach N; Krasniqi F; Schmidt A; Rothermundt C; Enoiu M; Eckhardt K; Berardi Vilei S; Rondeau S; Mey U
    Br J Haematol; 2016 Jul; 174(2):255-63. PubMed ID: 27018242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
    Ruan J; Martin P; Christos P; Cerchietti L; Tam W; Shah B; Schuster SJ; Rodriguez A; Hyman D; Calvo-Vidal MN; Smith SM; Svoboda J; Furman RR; Coleman M; Leonard JP
    Blood; 2018 Nov; 132(19):2016-2025. PubMed ID: 30181173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
    Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.